JonesResearch Starts Coverage on Atai Beckley & Mind Medicine with Buy Ratings
JonesResearch gives Buy ratings to Atai Beckley and Mind Medicine, highlighting potential in psychedelic drug development for depression and anxiety.
/ 4 items
#ATAI↓
Berenberg Rates ATAI Life Sciences Buy with $12 Target on Strong Pipeline
Berenberg maintains Buy rating on ATAI Life Sciences (ATAI) with $12 price target, citing exceptional progress, strong pipeline momentum, and upcoming Phase 3 trials for psychedelic treatments.
Jefferies Boosts Atai Life Sciences Price Target to $10 on FDA Breakthrough Win
Jefferies raises Atai Life Sciences price target to $10 following FDA Breakthrough Therapy Designation for depression drug BPL-003, citing 72% approval rate for BTD drugs.
Needham Sees Major Upside in Atai Life Sciences' Depression Treatment
Needham initiates Atai Life Sciences with Buy rating and $12 target, projecting BPL-003 could capture 20% market share by 2035 with $2.5B+ in sales.